Jarden Analysts See Some Hope for Cochlear -- Market Talk

Dow Jones

04/23

0134 GMT - Cochlear won't get a good start to its next fiscal year but there is still some cause for optimism, Jarden analysts say. While the hearing implant maker has slashed its FY 2026 profit guidance on weak unit sales, the Jarden analysts tell clients in a note that the Australian company's services segment appears to be rebounding into fiscal 2027. Elsewhere, they acknowledge that competition is making acoustics revenue growth unpredictable, but still cite 11% March-quarter growth as a positive. Jarden cuts its target price on the stock 25% to A$169.00 and maintains a neutral rating. Shares are down 1.4% at A$98.19. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 22, 2026 21:34 ET (01:34 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2629355070"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629355070\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629355070?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629355070","market":"fut","top_or_hot":-1,"title":"Jarden Analysts See Some Hope for Cochlear -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0134 GMT - Cochlear won't get a good start to its next fiscal year but there is still some cause for optimism, Jarden analysts say. While the hearing implant maker has slashed its FY 2026 profit guidance on weak unit sales, the Jarden analysts tell clients in a note that the Australian company's services segment appears to be rebounding into fiscal 2027. Elsewhere, they acknowledge that competition is making acoustics revenue growth unpredictable, but still cite 11% March-quarter growth as a positive. Jarden cuts its target price on the stock 25% to A$169.00 and maintains a neutral rating. Shares are down 1.4% at A$98.19. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 21:34 ET (01:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jarden Analysts See Some Hope for Cochlear -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJarden Analysts See Some Hope for Cochlear -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-04-23 09:34</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0134 GMT - Cochlear won't get a good start to its next fiscal year but there is still some cause for optimism, Jarden analysts say. While the hearing implant maker has slashed its FY 2026 profit guidance on weak unit sales, the Jarden analysts tell clients in a note that the Australian company's services segment appears to be rebounding into fiscal 2027. Elsewhere, they acknowledge that competition is making acoustics revenue growth unpredictable, but still cite 11% March-quarter growth as a positive. Jarden cuts its target price on the stock 25% to A$169.00 and maintains a neutral rating. Shares are down 1.4% at A$98.19. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 22, 2026 21:34 ET (01:34 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HOPE","symbol_name":"Hope Bancorp, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629355070","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629355070","pubTimestamp":1776908040,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0134 GMT - Cochlear won't get a good start to its next fiscal year but there is still some cause for optimism, Jarden analysts say. While the hearing implant maker has slashed its FY 2026 profit guidance on weak unit sales, the Jarden analysts tell clients in a note that the Australian company's services segment appears to be rebounding into fiscal 2027. Elsewhere, they acknowledge that competition is making acoustics revenue growth unpredictable, but still cite 11% March-quarter growth as a positive. Jarden cuts its target price on the stock 25% to A$169.00 and maintains a neutral rating. Shares are down 1.4% at A$98.19. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HOPE":"Hope Bancorp, Inc.","COH.AU":"COCHLEAR LTD","BK4211":"区域性银行","BK7007":"医疗保健设备"},"translate_title":"Jarden分析师看到耳蜗的一些希望——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOPE":1.5,"COH.AU":0.9},"content_text":"0134 GMT - Cochlear won't get a good start to its next fiscal year but there is still some cause for optimism, Jarden analysts say. While the hearing implant maker has slashed its FY 2026 profit guidance on weak unit sales, the Jarden analysts tell clients in a note that the Australian company's services segment appears to be rebounding into fiscal 2027. Elsewhere, they acknowledge that competition is making acoustics revenue growth unpredictable, but still cite 11% March-quarter growth as a positive. Jarden cuts its target price on the stock 25% to A$169.00 and maintains a neutral rating. Shares are down 1.4% at A$98.19. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 21:34 ET (01:34 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}